Neurizon Therapeutics Limited has released a press release.
Monepantel reformulation project continues to progress
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Earlier from Neurizon Therapeutics
- New patent secured in US for non-cancer applications
- Reformulation project achieves first milestones and on-track
- PharmAust secures core Europe patent
- PharmAust & Nihon Nohyaku Japan Enter Assignment Agreement
- Appendix 4E & Full Year Statutory Accounts 2017
Later from Neurizon Therapeutics
- Appendix 4C - Quarterly Report & Brief Company Update
- Epichem Update - progress on milestones and revenue targets
- New drugs patented for cancer in USA
- New MPL analogues show greater anti-cancer activity
- PharmAust Raises $1.873m via an Oversubscribed Placement
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics